November 15, 2026StocksTechnology·Neutral·clinical data
Nuvation Bio presents updated long-term Phase 2 J201 data for safusidenib in Grade 2 IDH1-mutant glioma at SNO Annual Meeting
Nuvation Bio presented updated long-term results from its Phase 2 J201 study of safusidenib, a selective mutant IDH1 inhibitor, in patients with Grade 2 IDH1-mutant glioma who had not previously received chemotherapy or radiotherapy, at the 31st SNO Annual Meeting in Philadelphia.
Detected & updated continuously · Source: Nebula
Story subjects